Page last updated: 2024-10-26

famotidine and Pancreatic Neoplasms

famotidine has been researched along with Pancreatic Neoplasms in 2 studies

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Altschul, M1
Simpson, KW1
Dykes, NL1
Mauldin, EA1
Reubi, JC1
Cummings, JF1
Pisegna, JR1
Norton, JA1
Slimak, GG1
Metz, DC1
Maton, PN1
Gardner, JD1
Jensen, RT1

Trials

1 trial available for famotidine and Pancreatic Neoplasms

ArticleYear
Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
    Gastroenterology, 1992, Volume: 102, Issue:3

    Topics: Adult; Aged; Cimetidine; Dose-Response Relationship, Drug; Duodenal Neoplasms; Famotidine; Female; F

1992

Other Studies

1 other study available for famotidine and Pancreatic Neoplasms

ArticleYear
Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.
    The Journal of small animal practice, 1997, Volume: 38, Issue:7

    Topics: Animals; Anti-Ulcer Agents; Antineoplastic Agents, Hormonal; Dog Diseases; Dogs; Dose-Response Relat

1997